Gilead Reports Success, but Offers Little Data, on Key Cancer Drug Trial

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

  • Order Reprints

  • Print Article

Gilead Sciences shares dropped sharply before recovering as the market opened, after a highly anticipated announcement of the results of a trial of the company’s breast cancer drug Trodelvy offered few details on its performance.

The company said the trial of Trodelvy in heavily treated patients with HR /HER2- metastatic breast cancer succeeded in showing a statistically significant improvement in progression-free survival compared with chemotherapy.